Morphological, functional and metabolic imaging biomarkers: Assessment of vascular-disrupting effect on rodent liver tumours

European Radiology

Volumn 20, Issue 8, 2010, Pages 2013-2026

  Wang, Huaijun ^a   Li, Junjie ^a   Chen, Feng ^a,b   De Keyzer, Frederik ^a   Yu, Jie ^a   Feng, Yuanbo ^a   Nuyts, Johan ^a   Marchal, Guy ^a   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Imaging biomarkers; Liver; Magnetic resonance imaging (MRI); Positron emission tomography (PET); Tumour; ZD6126

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; LIVER TUMOR; MALE; MICROANGIOGRAPHY; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FLUORODEOXYGLUCOSE F18; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; ORGANOPHOSPHORUS COMPOUNDS; RADIOPHARMACEUTICALS; RATS; TREATMENT OUTCOME;

EID: 77957942570     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1743-5     Document Type: Article

References (47)

1. Smith JJ, Sorensen AG, Thrall JH (2003) Biomarkers in imaging: realizing radiology's future. Radiology 227:633-638
2. Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102-125
3. Colburn WA (2003) Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 43:329-341
4. US FDA (2009) Medical imaging and drug development. http://www.fda.gov/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm092895.htm. Accessed 17 Sept 2009
5. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ (2004) Rationale for biomarkers and surrogate end points in mechanismdriven oncology drug development. Clin Cancer Res 10:3885-3896
6. Jain KK (2007) Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9:563-571
7. Kleespies A, Kohl G, Friedrich M, Ryan AJ, Barge A, Jauch KW, Bruns CJ (2005) Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. Neoplasia 7:957-966
8. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657
9. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498
10. Gotlieb AI (1990) The endothelial cytoskeleton: organization in normal and regenerating endothelium. Toxicol Pathol 18:603-617
11. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388-1393
12. Hermens AF, Barendsen GW (1967) Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur J Cancer 3:361-369
13. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Landuyt W, Bosmans H, Van Hecke P, Marchal G, Ni Y (2006) Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 239:554-562
14. Madhu B, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP (2006) The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 8:560-567
15. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, Hermans R (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234:756-764 (Pubitemid 40250819)
16. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G, Ni Y (2009) Treatment of rodent liver tumor with combretastatin A4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44:44-53
17. Hudson HM, Larkin RS (1994) Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 13:601-609
18. Feldkamp LA, Davis LC, Kress JW (1984) Practical cone-beam algorithm. J Opt Soc Am A 1:612-619
19. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y (2005) Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237:492-499
20. Tofts PS, Berkowitz BA (1993) Rapid measurement of capillary permeability using the early part of the dynamic Gd-DTPA MRI enhancement curve. J Magn Reson B 102:129-136
21. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T (1) - weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
22. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91-101
23. 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med 48:390-397
24. 18F-FDG: standardized uptake values in normal tissues. J Nucl Med 45:784-788
25. Eng J (2004) Sample size estimation: how many individuals should be studied? Radiology 227:309-313
26. McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC (2004) Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia 6:150-157
27. Vogel-Claussen J, Gimi B, Artemov D, Bhujwalla ZM (2007) Diffusionweighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol Ther 6:1469-1475
28. Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ (2007) Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia 9:382-391
29. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford M R L, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
30. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983
31. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vasculartargeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634
32. Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissueisolated and subcutaneous tumors: implications for therapy. Cancer Res 50:4478-4484
33. Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57:1047-1055
34. Jaffer S, Bleiweiss IJ (2004) Beyond hematoxylin and eosin-the role of immunohistochemistry in surgical pathology. Cancer Invest 22:445-465
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
36. Lang P, Wendland MF, Saeed M, Gindele A, Rosenau W, Mathur A, Gooding CA, Genant HK (1998) Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 206:227-235
37. Koh DM, Padhani AR (2006) Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 79:633-635
38. Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23:65-83
39. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599-1610
40. Koh D-M, Collins DJ (2007) Diffusionweighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635
41. Deng J, Rhee TK, Sato KT, Salem R, Haines K, Paunesku T, Mulcahy MF, Miller FH, Omary RA, Larson AC (2006) In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla. Invest Radiol 41:410-414
42. Chen G, Horsman MR, Pedersen M, Pang Q, Stødkilde-Jørgensen H (2008) The effect of combretastatin A4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. Acta Oncol 47:1071-1076
43. Cui Y, Zhang X-P, Sun Y-S, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894-900
44. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497-505
45. Avril N, Propper D (2007) Functional PET imaging in cancer drug development. Future Oncol 3:215-228
46. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J (2005) The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967-7985 (Pubitemid 41698738)
47. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN (2009) Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251:731-742